this author has yet to write their bio.
meanwhile lets just say that we are proud chen, chenyan contributed a whooping 385 entries.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that its u.s. subsidiary eisai inc. has launched its in-house discovered orexin receptor antagonist dayvigo™ (lemborexant) civ for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance in the u.s. on june 1, 2020.
abbvie gk (headquarters: minato-ku, tokyo; president: james feliciano, hereafter “abbvie”) and eisai co., ltd. (headquarters: tokyo; ceo: haruo naito, hereafter “eisai”) today announced an approval of partial changes in the marketing approval of humira® (generic name: adalimumab [recombinant], hereafter “humira”), a fully human anti- tnfα monoclonal antibody, for additional dosage and administration, specifically, to add an 80mg every-other-week (q2w) regimen as a treatment option for patients with hidradenitis suppurativa (hereafter “hs”) after the first 4 weeks of treatment.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate (multikinase inhibitor, product name: lenvima®, “lenvatinib”) and eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: halaven®, “eribulin”) will be given at the american society of clinical oncology (asco20 virtual scientific program*), from may 29 to 31, 2020.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito) announced today that it has been selected as “most honored company” and has been ranked first place overall in the biotechnology & pharmaceuticals sector of “the all-japan executive team”, released by the us financial information magazine “institutional investor”. this selection is based on eisai’s being ranked first place in “best ceos” and “best cfos”, respectively, in the sector.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and seikagaku corporation (headquarters: tokyo, president: ken mizutani, “seikagaku”) announced today that the companies have entered into an agreement for the co-development and marketing alliance in china for si-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by seikagaku.
the 6th gastrointestinal & liver disease treatment forum (hereinafter referred to as “give”), which was hosted by eisai china inc. and consisted of two sessions, completed successfully on mar. 20 and mar. 27 separately. in order to avoid people gathering during the epidemic outbreak, the forum was held online innovatively.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has submitted in japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: e7777) for relapsed or refractory cutaneous t-cell lymphoma (ctcl) and peripheral t-cell lymphoma (ptcl).
eisai china inc. kicked off the empowering neurology’s future (enf) successfully on mar. 22, 2020. to avoid people gathering during the epidemic period, the forum is held innovatively online to start a brand-new enf season, which will last from march 22ndto april 28th in seven sessions, one session per week.
in the face of the epidemic of covid-19, a large number of patients with normal medical needs can not go to hospital to seek medical treatment, and their diseases can not be treated well, which seriously decreases the quality of life of patients. eisai china holdings ltd. is joining hands with all sectors of society to fight against the epidemic, and escorting people to tide over the crisis.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and fuji yakuhin co., ltd. (headquarters: saitama, ceo: masayuki takayanagi, “fuji yakuhin”) announced today that they have concluded a license agreement concerning dotinurad (generic name), a treatment for hyperuricemia and gout discovered by fuji yakuhin, for development and distribution in china.
爱游戏app官网登录入口 copyright(c) 2011 eisai china lnc.all rights reserved.
021-62881220
本网站使用cookies以使您获得最佳的体验。为了继续浏览本网站，您需同意我们对cookies的使用。想要了解更多有关于cookies的信息，或不希望当您使用网站时出现cookies，请阅读我们的cookies声明！
we may request cookies to be set on your device. we use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
click on the different category headings to find out more. you can also change some of your preferences. note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
these cookies are strictly necessary to provide you with services available through our website and to use some of its features.
because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. you always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. but this will always prompt you to accept/refuse cookies when revisiting our site.
we fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. you are free to opt out any time or opt in for other cookies to get a better experience. if you refuse cookies we will remove all set cookies in our domain.
we provide you with a list of stored cookies on your computer in our domain so you can check what we stored. due to security reasons we are not able to show or modify cookies from other domains. you can check these in your browser security settings.
we also use different external services like google webfonts, google maps, and external video providers. since these providers may collect personal data like your ip address we allow you to block them here. please be aware that this might heavily reduce the functionality and appearance of our site. changes will take effect once you reload the page.
google webfont settings:
google map settings:
google recaptcha settings:
vimeo and youtube video embeds:
you can read about our cookies and privacy settings in detail on our privacy policy page.
privacy policy